X4 Pharmaceuticals (XFOR) EBT (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported EBT for 10 consecutive years, with -$16.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 37.15% year-over-year to -$16.2 million; the trailing twelve-month figure through Jun 2026 stood at -$90.2 million (up 11.28% YoY), and the FY2025 full-year result was -$79.2 million, down 113.13% from the prior year.
• EBT rose to -$16.2 million in Q2 2026 per XFOR's latest filing, from -$20.2 million in the prior quarter.
• Across five years, EBT topped out at $90.9 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
• Historically, EBT has averaged -$19.3 million across 5 years, with a median of -$22.9 million in 2022.
• The sharpest annual moves came in 2024 and 2026: EBT jumped 263.12% in 2024, then sank 6505.38% in 2026.
• Over 5 years, EBT stood at -$29.1 million in 2022, then jumped by 34.35% to -$19.1 million in 2023, then sank by 107.17% to -$39.6 million in 2024, then jumped by 39.53% to -$23.9 million in 2025, then soared by 32.48% to -$16.2 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$16.2 million, -$20.2 million, and -$23.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.